Kidney transplant patients may benefit from going off of certain immunosuppressive drugs

Jun 18, 2008

[B]Withdrawal of calcineurin inhibitors provides long-term health benefits and saves money[/B]
Withdrawing certain immunosuppressive drugs following kidney transplantation prolongs survival and saves money compared with keeping patients on these medications for life, according to a study appearing in the September 2008 issue of the Journal of the American Society Nephrology (JASN).

In this study, a lifetime Markov model was created to compare the cost-effectiveness of a sirolimus-based calcineurin inhibitor (CNI) withdrawal regimen (sirolimus plus steroids) with other common CNI-containing regimens in adult de novo renal transplantation patients. The findings indicate that in the long-run, the risks of the medications potentially outweigh their benefits.

Immunosuppressive drugs such as calcineurin inhibitors are critical after kidney transplantation to prevent organ rejection, particularly during the first year. However, a trade-off exists, because calcineurin inhibitors are associated with serious adverse effects, including renal dysfunction, infections, cancer, diabetes mellitus and cardiovascular-related events. Therefore, regimens need to be optimized over time so that patients can benefit from the drugs' short-term benefits but not be harmed by their long-term risks.

Head-to-head analyses of the short-term benefits and long-term risks of calcineurin inhibitors are limited. To compare the two, Dr. Stephanie Earnshaw of RTI Health Solutions in Research Triangle Park, NC, and her colleagues examined data from published studies and from the United States transplant registry.

Sirolimus, in combination with steroids, is currently the only immunosuppressive treatment regimen that is approved for use when calcineurin inhibitors are withdrawn. Therefore, Dr. Earnshaw's group compared treatments containing sirolimus plus steroids versus treatments that maintained the use of calcineurin inhibitors.

The researchers' decision-analytic model, using data published in the literature and reported by the US transplant registry, assumed that within the first 12 months following transplant surgery, sirolimus plus steroid therapy is associated with a greater risk of kidney allograft rejection than regimens that continue to use calcineurin inhibitors.


Other commonly used regimens include a calcineurin inhibitor such as cyclosporine or tacrolimus, plus mycophenolate mofetil and steroids. In this particular study, it was assumed that in the absence of induction therapy a total of 21.8% of patients taking sirolimus plus steroids experienced acute rejection within one year of transplantation, compared with 19.0% of patients taking cyclosporine plus mycophenolate mofetil and steroids, and 17.1% of patients taking tacrolimus plus mycophenolate mofetil and steroids.

However, it was revealed that overall, treatment with sirolimus plus steroids may be more efficacious and less costly than regimens that continued to use calcineurin inhibitors. Specifically, withdrawal of calcineurin inhibitors may prolong patients' lives and improve their kidney function.

It was estimated that the average number of grafts lost per patient over their remaining lifetime after initial kidney transplantation (patients can have more than one transplant) was 0.90 for patients taking sirolimus plus steroids, compared with 0.94 for patients in the cyclosporine group and 0.92 for patients in the tacrolimus group. Sirolimus plus steroids also may increase patient survival (11.43 years, compared with 11.37 years in the cyclosporine group and 11.13 years in the tacrolimus group.) Total lifetime costs per patient in the three groups were $472,799; $484,020; and $505,420, respectively.

According to the authors, these findings indicate "calcineurin inhibitor withdrawal not only shows potential for long-term clinical benefits, but also is expected to be cost-saving over a patient's life compared with the most commonly prescribed calcineurin inhibitor–containing regimens." They note that withdrawal of CNIs is an important option because clinicians consider the lifetime of the patient to be more important than the year that follows transplantation. It is important to note that this analysis relied on certain assumptions (such as the incidence of acute rejection per treatment arm and measures of renal function) due to limited availability of data. As such, additional research will be necessary to support these results.


Source: American Society of Nephrology

Explore further: India's meth addiction grows as criminals tap chemical hub

add to favorites email to friend print save as pdf

Related Stories

Sapphire talk enlivens guesswork over iPhone 6

6 hours ago

Sapphire screens for the next iPhone? Sapphire is second only to diamond in hardness scratch-proof properties, used in making LEDs, missiles sensors, and on screens for luxury-tier phones. Last year, the ...

The source of the sky's X-ray glow

9 hours ago

In findings that help astrophysicists understand our corner of the galaxy, an international research team has shown that the soft X-ray glow blanketing the sky comes from both inside and outside the solar system.

Recommended for you

Determine patient preferences by means of conjoint analysis

23 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 0